Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance

Breast Cancer Research and Treatment

Volumn 96, Issue 1, 2006, Pages 63-72

  Corte, Maria D ^a   Tamargo, Francisco ^a   Alvarez, Ana ^a,b   Rodriguez J C ^a,c   Vazquez J ^a,c   Sánchez, Rosario ^a   Lamelas, Maria L ^a,c   Gonzalez L O ^a,c   Allende, Maria T ^a,b   Garcia Muniz J L ^b   Fueyo, A ^a   Vizoso, F ^a,c  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL DE JOVE   (Spain)

Author keywords

Adjuvant tamoxifen; Breast cancer; Estrogen receptors; Progesterone receptors; Prognosis; Trefoil peptides

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN PS2; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DIPLOIDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; OUTCOME ASSESSMENT; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONTENT; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TISSUE LEVEL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; VARIANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; CYTOSOL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNORADIOMETRIC ASSAY; MIDDLE AGED; NEOPLASM INVASIVENESS; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 33645212423     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9041-7     Document Type: Article

References (30)

1. Wong WM, Poulsom R, Wright NA: Trefoil peptides. Gut 44: 890-895, 1999
2. Luqmani Y, Bennett C, Paterson I, Corbishley CM, Rio MC, Chambon P, Ryall G: Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 44: 806-812, 1989
3. Hahnel E, Robbins P, Hahnel R: Expression of the pS2 gene in normal breast tissue. Breast Cancer Res Treat 28: 295-297, 1993
4. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P: Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res 12: 2861-2878, 1984
5. Rio MC, Chambon P: The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 2: 269-274, 1990
6. Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G: PS2 in breast cancer-alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68: 374-379, 1993
7. Besse G, Kwiatkowski F, Gaillard G, Daver A, Dalifard I, Basuyau JP, Brunelle P, Wafflart J, Angibeau RM, Auvray E: [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study]. Bull Cancer 81: 289-296, 1994
8. Soubeyran I, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34: 119-128, 1995
9. Foekens JA, van Putten WL, Portengen H, de Koning HY, Thirion B, Alexieva-Figusch J, Klijn JG: Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 11: 899-908, 1993
10. Soubeyran I, Quenel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 74: 1120-1125, 1996
11. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89: 111-117, 2000
12. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835, 1994
13. Ioakim-Liossi A, Karakitsos P, Aroni K, Markopoulos C, Delivelioti K, Gogas J, Kyrkou K: DNA ploidy and pS2 protein expression in breast cancer. Cytopathology 8: 171-176, 1997
14. Inaji H, Koyama H, Motomura K, Noguchi S: Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 37: 89-92, 1996
15. Nichols PH, Ibrahim NB, Padfield CJ, Cawthorn SJ: Correlation of pS2 expression of involved lymph nodes in relation to primary breast carcinoma. Eur J Surg Oncol 21: 151-154, 1995
16. Pujol P, Daures JP, Brouillet JP, Maudelonde T, Rochefort H, Grenier J: Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer. Br J Cancer 79: 909-914, 1999
17. Reshkin SJ, Tedone T, Correale M, Mangia A, Casavola V, Paradiso A: Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies. Cell Prolif 32: 107-118, 1999
18. Harding C, Osundeko O, Tetlow L, Faragher EB, Howell A, Bundred NJ: Hormonally regulated proteins in breast secretions are markers of target organ sensitivity. Br J Cancer 82: 354-360, 2000
19. Luqmani YA, Ricketts D, Ryall G, Turnbull L, Law M, Coombes RC: Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer 54: 619-623, 1993
20. Robbins PD, Hahnel E, Sterrett GF, Harvey J, Carrello S, Hahnel R: Expression of the pS2 gene in breast cancer - a comparison of pS2 protein radioimmunoassay and immunohistochemistry. Pathology 25: 255-260, 1993
21. Spyratos F, Andrieu C, Hacene K, Chambon P, Rio MC: pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 69: 394-397, 1994
22. Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MC: Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274: 259-262, 1996
23. Calnan DP, Westley BR, May FE, Floyd DN, Marchbank T, Playford RJ: The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol 188: 312-317, 1999
24. Bossenmeyer-Pourie C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C, Rio MC: The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol 157: 761-770, 2002
25. Williams R, Stamp GW, Gilbert C, Pignatelli M, Lalani EN: pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3-D collagen gel. J Cell Sci 109(Pt 1): 63-71, 1996
26. Prest SJ, May FE, Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. Faseb J 16: 592-594, 2002
27. Brown AM, Jeltsch JM, Roberts M, Chambon P: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 81: 6344-6348, 1984
28. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR: High expression of the trefoil protein TFF1 in interval breast cancers. Am J Pathol 159: 215-221, 2001
29. Martin V, Ribieras S, Song-Wang XG, Lasne Y, Frappart L, Rio MC, Dante R: Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J Cell Biochem 65: 95-106, 1997
30. Nunez AM, Berry M, Imler JL, Chambon P: The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. Embo J 8: 823-829, 1989